Purine–Hydrazone Scaffolds as Potential Dual EGFR/HER2 Inhibitors

Purine–Hydrazone Scaffolds as Potential Dual EGFR/HER2 Inhibitors

<b>Background/Objectives:</b> The dual targeting of epidermal growth factor receptor (EGFR) and human epidermal growth factor receptor 2 (HER2) represents an effective approach for cancer treatment. The current study involved the design, synthesis, and biological evaluation of a new seri...

Full description

Saved in:

Bibliographic Details
Main Authors:	Fatemah S. Albalawi, Mashooq A. Bhat, Ahmed H. Bakheit, A. F. M. Motiur Rahman, Nawaf A. Alsaif, Alan M. Jones, Isolda Romero-Canelon
Format:	Article
Language:	English
Published:	MDPI AG 2025-07-01
Series:	Pharmaceuticals
Subjects:	cancer EGFR HER2 EGFR- and HER2-driven cancers purine/hydrazone-containing compounds lapatinib
Online Access:	https://www.mdpi.com/1424-8247/18/7/1051
Tags:	Add Tag No Tags, Be the first to tag this record!

Similar Items

GRHL2-HER3 and E-cadherin mediate EGFR-bypass drug resistance in lung cancer cells
by: Fumiya Ito, et al.
Published: (2025-01-01)

Lapatinib plus transtuzumab for HER-2 positiva metastatic breast cancer: Experience of use
by: C. García-Muñoz, et al.
Published: (2014-03-01)

Induction of SUSD2 by STAT3 Activation Is Associated with Tumor Recurrence in HER2-Positive Breast Cancer
by: Yisun Jeong, et al.
Published: (2024-12-01)

Targeting PGK1 as a Novel strategy to regulate the sensitivity of HER2 positive gastric cancer to lapatinib
by: Xiaochen Ni, et al.
Published: (2025-07-01)

Molecular Docking and Pharmacological In Silico Evaluation of Camptothecin and Related Ligands as Promising HER2-Targeted Therapies for Breast Cancer
by: Elmer Joel Millan-Casarrubias, et al.
Published: (2025-03-01)

Computational molecular insights into ibrutinib as a potent inhibitor of HER2-L755S mutant in breast cancer: gene expression studies, virtual screening, docking, and molecular dynamics analysis
by: Tamizhini Loganathan, et al.
Published: (2025-03-01)

Synthesis, Antitumor Activities, and Apoptosis-Inducing Activities of Schiff’s Bases Incorporating Imidazolidine-2,4-dione Scaffold: Molecular Docking Studies and Enzymatic Inhibition Activities
by: Fhdah S. Alanazi, et al.
Published: (2025-03-01)

Olası Trastuzumab Kullanımına Bağlı Gelişen Pyojenik Granülom
by: Hilmi Cevdet Altınyazar, et al.
Published: (2013-01-01)

Improving treatment outcomes for patients with HER2‑positive breast cancer using neoadjuvant double HER2 blockade
by: V. F. Semiglazov, et al.
Published: (2024-11-01)

Simultaneous Occurrence of HER2 Mutations in EGFR Mutant NSCLC: Case Reports
by: Blerina Resuli, MD, et al.
Published: (2024-12-01)

Trastuzumab Rechallenge in HER2-Positive Metastatic Breast Cancer: A Promising Strategy for Enhanced Progression-Free Survival Post Ado-Trastuzumab Emtansine Progression
by: Yunus Emre Altıntaş, et al.
Published: (2024-12-01)

Multilineal treatment strategy of HER2-positive metastatic breast cancer (clinical case)
by: A. F. Nasretdinov, et al.
Published: (2021-06-01)

TCHL – a phase II neo-adjuvant study assessing TCH (docetaxel, carboplatin and trastuzumab) and TCHL (docetaxel, carboplatin, rastuzumab and lapatinib) in HER-2 positive breast cancer patients: a 5-year follow-up with serum biomarker analysis
by: John Crown, et al.
Published: (2025-06-01)

HER3 targeting with an antibody‐drug conjugate bypasses resistance to anti‐HER2 therapies
by: Lucía Gandullo‐Sánchez, et al.
Published: (2020-04-01)

Survival outcomes for HER2-low breast cancer: Danish national data
by: Michael Sode, et al.
Published: (2024-11-01)

HER2-Positive Serous Endometrial Cancer Treatment: Current Clinical Practice and Future Directions
by: Dimitrios Papageorgiou, et al.
Published: (2024-12-01)

Accuracy of human epidermal growth factor receptor 2 (HER2) immunohistochemistry scoring by pathologists in breast cancer, including the HER2-low cutoff
by: Agata Wróbel, et al.
Published: (2025-04-01)

Prevalence and concordance of HER2-low and HER2-ultralow status between historical and rescored results in a multicentre study of breast cancer patients in China
by: Hong Lv, et al.
Published: (2025-03-01)

Design, synthesis, and antiproliferative activity of new 5-ethylsulfonyl-indazole-3-carbohydrazides as dual EGFR/VEGFR-2 kinases inhibitors
by: Lamya H. Al-Wahaibi, et al.
Published: (2025-12-01)

Potential prognostic value of HER2/CEP17 FISH ratio in HER2-positive non-metastatic breast cancer: a real-world study
by: Fangchao Zheng, et al.
Published: (2025-05-01)

Discussion on the mechanism of HER2 resistance in esophagogastric junction and gastric cancer in the era of immunotherapy
by: Yan Zhang, et al.
Published: (2025-12-01)

Target therapy in treatment of HER2-positive breast cancer
by: A. S. Belokhvostova, et al.
Published: (2016-02-01)

The physiological limits of bispecific monoclonal antibody tissue targeting specificity
by: Armin Sepp, et al.
Published: (2025-12-01)

Paclitaxel-related type I Kounis Syndrome in a very young patient with HER2-positive breast cancer and the role of genomics to disentangle a complex therapeutic scenario: a case report and narrative review
by: Javier Muñoz, et al.
Published: (2025-06-01)

HER2-low breast cancer. Diagnostics, treatment and its adverse events
by: Hanna Bartkowiak, et al.
Published: (2024-12-01)

Advances in research and current challenges in the treatment of advanced HER2-low breast cancer
by: Qiang Qin
Published: (2025-03-01)

Metastasizing Maxillary Ameloblastoma: Report of a Case with Molecular Characterization
by: Matteo Rotellini, et al.
Published: (2016-03-01)

EGFR inhibitors in the treatment of colorectal cancer
by: M. В. Zabelin, et al.
Published: (2018-09-01)

Analysis of factors influencing the efficacy of NAC and prognosis between HER2-zero and HER2-low HR negative breast cancer
by: Jing-Jing Liu, et al.
Published: (2024-11-01)

The effectiveness of three months EGFR-CTH therapy in palliative colorectal cancer
by: Maciej Pawel Jankowski, et al.
Published: (2025-01-01)

Fully automatic HER2 tissue segmentation for interpretable HER2 scoring
by: Mathias Öttl, et al.
Published: (2025-04-01)

[18F]FDG PET/CT volumetric biomarkers for non-invasive prediction of HER2 expression in breast cancer patients
by: Mai ELahmadawy, et al.
Published: (2025-01-01)

Prediction model for assessing HER2 status patient with invasive ductal carcinoma based on clinical parameters and ultrasound features: a dual-center study
by: Lei Zhou, et al.
Published: (2025-07-01)

HER2-Low Breast Cancer—Current Knowledge and Future Directions
by: Abeer M. Shaaban, et al.
Published: (2025-04-01)

Clinical characteristics and therapeutic direction of HER2 low-expression breast cancer
by: Linlin Zhou, et al.
Published: (2025-02-01)

Progress of Research on Advanced Non-Small Cell Lung Cancer with HER-2 Mutation
by: Liang ZHANG, et al.
Published: (2025-02-01)

Current approaches to the treatment of HER2‑positive breast cancer with brain metastases
by: T. Yu. Semiglazova, et al.
Published: (2021-06-01)

Assessment of the effectiveness of surgical resections following tyrosine kinase inhibitor therapy in patients with EGFR-mutated stage III–IV lung adenocarcinoma
by: E. V. Levchenko, et al.
Published: (2023-02-01)

Immunomorphological specifcity of HER2-low breast cancer
by: I. V. Mikhailov, et al.
Published: (2024-11-01)

Identification of HER2-over-expression, HER2-low-expression, and HER2-zero-expression statuses in breast cancer based on 18F-FDG PET/CT radiomics
by: Xuefeng Hou, et al.
Published: (2025-05-01)